Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1721-1738 of 1,738 trials

Acromegaly: ALXN2420 Treatment Study

We are studying whether the new drug ALXN2420 can help lower hormone levels and improve symptoms in adults with acromegaly when used with standard treatments. This trial compares ALXN2420 to a placebo to assess its effectiveness.

Acromegaly1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinology

Advanced Solid Tumors: S095035 Treatment Study

We are investigating the safety and effectiveness of S095035, alone and with TNG462, for adults with advanced solid tumors that have a specific genetic deletion. This study aims to find the best dose and assess how well the treatment works.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Gastrointestinal Tumors: OncoGreen Imaging Study

We are testing a new imaging technique using OncoGreen to help surgeons better visualize tumors during surgery. This study is for patients with gastrointestinal tumors who are having surgery to remove their tumors.

Digestive System Tumors>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyInternal MedicineOncology

Atrial Fibrillation: AP31969 Medication Study

We are testing a new medication, AP31969, for people with atrial fibrillation to see if it helps control their heart rhythm and improve their quality of life. The study will also evaluate the safety of this treatment.

Atrial Fibrillation3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine

Gastric Cancer: Intraperitoneal Irinotecan Study

We are exploring a new treatment combining intraperitoneal irinotecan with standard therapy for patients with gastric cancer that has spread to the abdomen. This study aims to evaluate its safety, effectiveness, and impact on quality of life.

Gastric Peritoneal Metastases>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Immunotherapy for High-Risk Oral Disorders: APHRODITE Trial

We are testing a new immunotherapy to see if it can prevent high-risk oral disorders from turning into cancer. The study will also look at the treatment's safety and its effects on patients' quality of life.

Oral Disorders>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyOtolaryngology

Metastatic Non-Small Cell Lung Cancer: BMS-986504 Treatment Study

We are studying a new drug, BMS-986504, combined with pembrolizumab and chemotherapy for patients with metastatic non-small cell lung cancer and a specific genetic deletion. The goal is to see if this combination improves survival compared to a placebo treatment.

Metastatic Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)Investigational MedicinesCost ReimbursementOncology

IgA Nephropathy: Atacicept Treatment Study

We are testing a new medication, atacicept, to see if it helps patients with IgA nephropathy by reducing a specific protein in the blood. We will also monitor its safety and how it affects other immune factors.

IgA Nephropathy (Berger's Disease)1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNephrology

Migraine Study: Effects of Cilostazol

We are investigating how cilostazol affects migraine headaches in men and women without aura. The study looks at potential differences in response based on sex.

Migraine6-12 monthsSafety phase (I)Efficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurology

Cangrelor for Acute Ischemic Stroke Treatment

We are studying the safety and effectiveness of an intravenous medication called Cangrelor for patients with acute ischemic stroke and significant carotid artery blockage. This trial aims to see if it helps improve blood flow during emergency stenting procedures.

Ischemic Stroke with Large Artery Occlusion>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

TAR-0520 Gel for Preventing Nerve Damage in Breast Cancer Patients

We are studying whether TAR-0520 Gel can safely prevent nerve damage and nail changes in patients receiving taxane chemotherapy for breast cancer.

Chemotherapy-Induced Peripheral Neuropathy6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesInternal MedicineNeurologyOncology

Zoldonrasib for RAS G12D-Mutant Non-Small Cell Lung Cancer

We are studying the effects of zoldonrasib in patients with RAS G12D-mutant non-small cell lung cancer who have been previously treated. The goal is to see how well it works and how safe it is compared to existing treatments.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Advanced Solid Tumors: MK-1084 Treatment Study

We are studying the effects of MK-1084, both alone and with cetuximab, in patients with advanced solid tumors that have a KRAS G12C mutation. The goal is to see how well these treatments work and how safe they are.

Malignant Neoplasm with KRAS G12C Mutation>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: Tulisokibart Study

We are testing a new medication called tulisokibart for people with rheumatoid arthritis to see if it helps reduce symptoms better than a placebo. The study will also assess the safety and tolerability of this treatment.

Rheumatoid Arthritis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology

Blood Cancer Treatment: Ciltacabtagene Autoleucel

We are studying the effects of a new infusion treatment for patients with blood cancers. The trial compares different ways of administering the treatment to see which is more effective and safe.

Newly Diagnosed Multiple MyelomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

CIT-013 for Inflammatory Mediated Immune Diseases

We are studying how a new treatment, CIT-013, spreads in the body of patients with inflammatory mediated immune diseases. We also want to learn about its safety and how the body handles it.

Inflammatory Mediated Immune Diseases≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Influenza Vaccine Study for Adults

We are assessing a new mRNA-based vaccine to see how well it boosts the immune response and its safety in adults aged 18 and older. This study aims to improve protection against seasonal influenza.

Human Influenza6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious Diseases

CTNNB1 Syndrome: Gene Therapy Study for Kids

We are testing a new gene therapy given through an injection in the brain for children with CTNNB1 syndrome. The study aims to see if it is safe and if it may help improve their condition.

CTNNB1 Syndrome1-2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics